Effects of Vented Base Feeding Bottle in Preterm Infants With GERD Symptoms.

NCT ID: NCT03031288

Last Updated: 2020-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2018-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the study is to evaluate the effects of vented base bottles on respiration-swallow patterns and on gastroesophageal refluxes in preterm infants with clinical suspect of gastroesophageal reflux disease (GERD).

In this crossover-randomized study, we compared the effects of standard feeding bottles (A) versus vented base feeding bottles (B) on a group of patients with at least 2 clinical GERD symptoms. 24 hours of synchronized cardiorespiratory (CR) and Esophageal Multichannel intraluminal impedance (MII/pH) monitoring were evaluated for each patient. During this period, patients were fed alternatively with feeding bottle A and B.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In preterm infants a deficit of both coordination and gastro-intestinal motility is often the underpinning cause of oxygen desaturations and gastro-esophageal reflux. Breastfeeding enhances the maturation of the respiration-swallow mechanism. For this reason, a feeding bottle that best recreates the physiological sucking from the maternal breast is highly desirable in non-breastfed newborns.

Population: newborns referred to esophageal Multichannel Intraluminal Impedance and pH-metry (MII/pH) combined with cardiorespiratory (CR) monitoring for GERD or cardio-respiratory symptoms

Materials and methods: we compare the effects of traditional feeding bottles (A) versus vented base feeding bottles (B) on cardiorespiratory and reflux events in newborns undergoing 24 hours synchronized CR and MII/pH monitoring. During the exam, newborns are fed, alternatively, by feeding bottle A and B with human milk or formula. Some training meals are offered the day before monitoring to get newborns enrolled into the study used to vented base feeding bottles.

Cardiorespiratory monitoring is performed through VitaGuard VG3100® (Getemed Medizin- und Informationstechnik AG, Teltow, Germany) based on Masimo Signal Extraction Technology (SET)® (Masimo Corp., Irvine, CA, USA). It operates with a blood oxygen saturation (SpO2) detector, placed on the right wrist, and 3 thoracic electrodes. This instrument is able to record ECG, heart rate, SpO2 and thoracic plethysmographic curve. The signals are analyzed with VitaWin 3® software (Getemed Medizin - und Informationstechnik AG, Teltow, Germany), by filtering artifacts.

The MII/pH monitoring is performed through a neonatal catheter (Infant Comfort TEC®) with 7 impedence electrodes (creating 6 impedance channels) and one pH detector able to cover the whole distance from the pharynx to the lower esophageal sphincter (LES) (channel 1). The pH detector is placed within channel 1, 1.5 cm above the LES. The correct positioning of the catheter is measured through fluoroscopy and eventually corrected. Data obtained from impedance channels that result proximal to the superior esophageal sphincter are excluded from the analysis. The acquisition and recording of MII/pH data are performed through Sleuth System, Sandhill Scientific Inc., Highlands Ranch, Colorado, USA. The analysis of MII/pH tracings is made visually by a single operator using BioView 5.3.4 software (Sleuth System, Sandhill Scientific Inc., Highlands Ranch, Colorado, USA).

The variables analyzed are listed as follows:

Clinical variables:

* feeding time (min)
* feeding total volume (mL)
* n. GER during feeding
* n. GER in the post-prandial period (150 min after feeding)

Cardiorespiratory variables:

* frequency of apnea, desaturation and bradycardia during feeding
* frequency of apnea, desaturation and bradycardia during post-prandial period
* mean duration of apnea during feeding and post-prandial period
* mean and minimum desaturation level during feeding and post-prandial period
* mean and minimum heart rate during feeding and post-prandial period

MII/pH variables:

* Swallow frequency during feeding and post-prandial period (events/h)
* Bolus Presence Time (BPT): seconds between bolus entry and bolus exit in the distal channel
* Bolus Head Advancing Time (BHAT): seconds between bolus entry in proximal channel and entry in distal channel
* Bolus Head Advancing Time Corrected for Esophageal Length (BHATc): BHAT corrected for esophageal length (BHATc = BHAT / esophageal length)
* Reflux pH: minimum pH value registered during each GER event. It classifies refluxes into 3 different types: acid (pH \< 4), weakly acid (pH 4-7) and weakly alkaline (pH \> 7)
* GER frequency, (events/h)
* Bolus Clearance Time (BCT): reflux duration, recorded at distal channel (s)
* Bolus Reflux Extent (BRE), (n. channels)
* Proximal GER frequency (events/h)
* Bolus Exposure Index (BEI): percentage of time in which GER involves esophagus during MII/pH monitoring
* Reflux Index (RI): percentage of time during which pH falls below 4 during MII/pH monitoring

Randomization: the alternate use of feeding bottles A and B is set by a binary random sequencing generated by Microsoft Office Excel software that indicates the first feeding bottle to be used. This is a single-blind study since the sequence is unknown to the specialist in charge of reporting MII/pH and CR monitoring.

Statistical analysis:

The analysis is made with Statistical Software Package For Windows® (StatSoft, Inc., Tulsa, Oklahoma, USA). Kolmogorov-Smirnov test and exploratory data analysis are used to define normality range. Data will be expressed as mean and standard deviation (SD), or as median and interquartile range if more appropriate. Differences among cardiorespiratory and MII/pH variables will be evaluated with Student paired T test or Wilcoxon test if more appropriate. Significance will be considered as p\<0.05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GERD Apnea Neonatal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Start feeding with Device A, "standard"

Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)

Group Type EXPERIMENTAL

A

Intervention Type DEVICE

standard bottle

B

Intervention Type DEVICE

vented base bottle

Start feeding with Device B, "vented"

Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)

Group Type EXPERIMENTAL

A

Intervention Type DEVICE

standard bottle

B

Intervention Type DEVICE

vented base bottle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A

standard bottle

Intervention Type DEVICE

B

vented base bottle

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* weight ≥ 1500 g at the time of examination
* at least 2 GERD symptoms
* exclusive enteral feeding
* parents' informed consent

Exclusion Criteria

* congenital abnormalities
* perinatal asphyxia
* respiratory, genetic, metabolic, infectious and/or neurologic disease
* pharmacological therapies, in the last 7 days, able to affect esophageal motility
Minimum Eligible Age

1 Week

Maximum Eligible Age

3 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Turin, Italy

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francesco Cresi, MD, PhD

MD PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesco Cresi, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University of Turin, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospedale S.Anna di Torino

Torino, (TO), Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

feeding-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.